The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03039335|
Recruitment Status : Completed
First Posted : February 1, 2017
Last Update Posted : July 16, 2018
|Condition or disease|
|Alpha 1-Antitrypsin Deficiency|
|Study Type :||Observational|
|Actual Enrollment :||43 participants|
|Official Title:||The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency: Assessing the Association Between Diagnostic Delay and Worsened Clinical Status|
|Actual Study Start Date :||December 15, 2016|
|Actual Primary Completion Date :||April 15, 2018|
|Actual Study Completion Date :||April 15, 2018|
Adults with an AAT Deficiency
Subjects over the age of 18 that have been recently diagnosed with an Alpha-1 Antitrypsin deficiency will be enrolled into the study to observe the interval between first symptom and initial diagnosis.
- Recruitment [ Time Frame: 3 months ]Track the number of subjects enrolled to determine if recruitment strategies need to be altered.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03039335
|United States, Maryland|
|Fulton, Maryland, United States, 20759|
|Principal Investigator:||Christopher Sanders||CEO of Biocerna LLC|